Shenzhen Kangtai Biological Products
From Wikipedia, the free encyclopedia
22°32′48″N 113°56′37″E / 22.5467°N 113.9437°E
| Company type | Public | ||||||
|---|---|---|---|---|---|---|---|
| SZSE: 300601 | |||||||
| ISIN | CNE100002Q33  | ||||||
| Founded | September 8, 1992 | ||||||
| Founder | Du Weimin[1] | ||||||
| Headquarters | 6 Kefa Road, Science and Technology Park, Nanshan District, Shenzhen, , China | ||||||
Number of employees | 2043[2] | ||||||
| Chinese name | |||||||
| Simplified Chinese | 深圳康泰生物制品股份有限公司 | ||||||
| |||||||
| Website | en | ||||||
Shenzhen Kangtai Biological Products (Chinese: 深圳康泰生物制品股份有限公司, SZSE: 300601), also known as BioKangtai (Chinese: 康泰生物), is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products.[2]
Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China.[3][4][1]
